Overview

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The study is a prospective, single arm, non-randomized, open label pilot trial, designed to study the safety, toxicity, feasibility and preliminary efficacy of a medical device, the NovoTTF-100L(O) concomitant with weekly paclitaxel in recurrent ovarian carcinoma patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NovoCure Ltd.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel